TECH Bio-Techne
Durable reagent moat, but the price still assumes a growth recovery that flat revenue hasn't confirmed.
The story
Bio-Techne sells research reagents (proteins, antibodies), spatial biology tools and diagnostics. The reagent franchise has a real moat: scientists stick with validated, often-cited inputs, which keeps gross margins high. Revenue has been flat at about $1.22B because biopharma and academic funding are weak. GAAP operating margin has recovered from 8.8% to 20.6%, but growth has not returned yet. This is a mature, high-quality business waiting for its end markets to recover, not an early-stage compounder.
Growth, margin, risk and horizon are unchanged. Revenue is still flat, and the margin rebound to 20.6% supports the existing 30% target rather than a higher one. I raised sales-to-capital from 1.2 to 1.5 (+25%) because capex is about $0.03B against $0.10B of D&A, so organic reinvestment is light. The reported 0.53 ratio is weighed down by acquisition goodwill, not by what it costs to grow. The market price implies sustained growth of 8-10%, and I won't assume that until the revenue data shows it.
Value drivers
| Revenue growth (Y1) | 4.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 30.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.50 |
| Beta | 1.00 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 1.71B |
| PV of terminal value | 1.78B |
| Equity value | 3.52B |
| ÷ shares → per share | $22.46 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 1.26B | 4.0% | 22.5% | 214.65M | 32.40M | 182.25M | 166.58M |
| 2 | 1.31B | 3.9% | 24.4% | 241.78M | 33.23M | 208.55M | 174.23M |
| 3 | 1.36B | 3.9% | 26.2% | 270.56M | 34.05M | 236.51M | 180.60M |
| 4 | 1.42B | 3.8% | 28.1% | 301.06M | 34.87M | 266.19M | 185.78M |
| 5 | 1.47B | 3.8% | 30.0% | 333.32M | 35.68M | 297.63M | 189.87M |
| 6 | 1.53B | 3.7% | 30.0% | 345.72M | 36.49M | 309.24M | 180.31M |
| 7 | 1.58B | 3.7% | 30.0% | 358.40M | 37.28M | 321.12M | 171.14M |
| 8 | 1.64B | 3.6% | 30.0% | 371.34M | 38.06M | 333.28M | 162.35M |
| 9 | 1.70B | 3.6% | 30.0% | 384.55M | 38.83M | 345.72M | 153.93M |
| 10 | 1.76B | 3.5% | 30.0% | 398.01M | 39.58M | 358.42M | 145.86M |
Key risks
- Prolonged weakness in biopharma and academic funding (NIH budget cuts, biotech capital scarcity) keeps growth near zero
- Spatial biology and diagnostics acquisitions fail to earn their cost of capital, leading to further impairments and margin swings
- Valuation multiple compresses if a recovery is delayed past 2027
Catalysts
- Biotech funding and pharma R&D spending recover, bringing reagent volumes back to high single-digit growth
- Margin expansion toward 30%+ as one-time restructuring costs fade and spatial and cell-therapy lines scale